R
Robert A. Price
Researcher at Fox Chase Cancer Center
Publications - 122
Citations - 2691
Robert A. Price is an academic researcher from Fox Chase Cancer Center. The author has contributed to research in topics: Dosimetry & Prostate cancer. The author has an hindex of 28, co-authored 117 publications receiving 2510 citations. Previous affiliations of Robert A. Price include University of Lisbon & City University London.
Papers
More filters
Journal ArticleDOI
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
Alan Pollack,Alexandra L. Hanlon,Eric M. Horwitz,Steven J. Feigenberg,Andre Konski,Benjamin Movsas,Richard E. Greenberg,Robert G. Uzzo,Charlie Ma,S. McNeeley,Mark K. Buyyounouski,Robert A. Price +11 more
TL;DR: Hypofractionation at 2.7 Gy per fraction to 70.2 Gy was well tolerated acutely using the planning conditions described, and only the combined rectal DVH parameter of V65 Gy/V50 Gy was significant for GI toxicity and the bladder volume for GU toxicity.
Journal ArticleDOI
An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee.
Aaron M. Allen,Todd Pawlicki,Lei Dong,E Fourkal,Mark K. Buyyounouski,Keith A. Cengel,John P. Plastaras,M.K. Bucci,Torunn I. Yock,Luisa Bonilla,Robert A. Price,Eleanor E.R. Harris,Andre Konski +12 more
TL;DR: Current data do not provide sufficient evidence to recommend PBT in lung cancer, head and neck cancer, GI malignancies, and pediatric non-CNS malignancy, but there is evidence for the efficacy of PBT but no suggestion that it is superior to photon based approaches.
Journal ArticleDOI
MRI-based treatment planning for radiotherapy: Dosimetric verification for prostate IMRT
Lili Chen,Robert A. Price,Lu Wang,Jinsheng Li,Lihong Qin,S. McNeeley,Charlie Ma,Gary M. Freedman,Alan Pollack +8 more
TL;DR: In this paper, the authors investigated the dosimetric accuracy of MRI-based treatment planning for prostate IMRT and found that the absolute dose agreement for the planning target volume was within 2% between CT-based and MR-based plans and 3% between measured dose and dose predicted by the planning system.
Journal ArticleDOI
Dose selection for prostate cancer patients based on dose comparison and dose response studies.
Gerald E. Hanks,Alexandra L. Hanlon,Wayne H. Pinover,Eric M. Horwitz,Robert A. Price,Timothy E. Schultheiss +5 more
TL;DR: Dose response varies by patient subgroup, and appropriate dose can be estimated for up to six subdivisions of prostate cancer patients, and the appropriate use of high dose with 3D CRT results in 5-year cure rates that equal or exceed other treatments.
Journal ArticleDOI
Radiation therapy dose escalation for prostate cancer: a rationale for IMRT
Alan Pollack,A.L. Hanlon,Eric M. Horwitz,Steven J. Feigenberg,Robert G. Uzzo,Robert A. Price +5 more
TL;DR: The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described.